154 related articles for article (PubMed ID: 38064663)
1. Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.
Baumgartner F; Baer C; Bamopoulos S; Ayoub E; Truger M; Meggendorfer M; Lenk M; Hoermann G; Hutter S; Müller H; Walter W; Müller ML; Nadarajah N; Blombery P; Keller U; Kern W; Haferlach C; Haferlach T
Blood; 2024 Mar; 143(12):1139-1156. PubMed ID: 38064663
[TBL] [Abstract][Full Text] [Related]
2. Cytopenia, dysplasia, and monocytosis: a precursor to chronic myelomonocytic leukemia or a distinct subgroup? Case reports and review of literature.
Singh ZN; Post GR; Kiwan E; Maddox AM
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):293-7. PubMed ID: 21658659
[TBL] [Abstract][Full Text] [Related]
3. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
4. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
5. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Calvo X; Garcia-Gisbert N; Parraga I; Gibert J; Florensa L; Andrade-Campos M; Merchan B; Garcia-Avila S; Montesdeoca S; Fernández-Rodríguez C; Salido M; Puiggros A; Espinet B; Colomo L; Roman-Bravo D; Bellosillo B; Ferrer A; Arenillas L
Blood Adv; 2020 Oct; 4(20):5285-5296. PubMed ID: 33108455
[TBL] [Abstract][Full Text] [Related]
6. [MDS & CMML: Diagnostic and classification].
Wagner-Ballon O; Kosmider O
Bull Cancer; 2023 Nov; 110(11):1106-1115. PubMed ID: 37453834
[TBL] [Abstract][Full Text] [Related]
7. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
8. Response to azacitidine in patients with chronic myelomonocytic leukemia according to overlap myelodysplastic/myeloproliferative neoplasms criteria.
Triguero A; Xicoy B; Zamora L; Jiménez MJ; García O; Calabuig M; Díaz-Beyá M; Arzuaga J; Ramos F; Medina A; Bernal T; Talarn C; Coll R; Collado R; Chen TH; Borrás J; Brunet S; Marchante I; Marco V; López-Cadenas F; Calbacho M; Simiele A; Cortés M; Cedena MT; Pedreño M; Aguilar C; Pedró C; Fernández M; Stoica C; Ribera JM; Sanz G
Leuk Res; 2022 May; 116():106836. PubMed ID: 35405632
[TBL] [Abstract][Full Text] [Related]
9. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
[TBL] [Abstract][Full Text] [Related]
10. The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS.
Xicoy B; Triguero A; Such E; García O; Jiménez MJ; Arnán M; Bernal T; Diaz-Beya M; Valcárcel D; Pedro C; Ramos F; Amigo ML; Collado R; Palomo L; Ardanaz MT; Cedena MT; Grau J; Zamora L; Sanz G
Leuk Res; 2018 Jul; 70():34-36. PubMed ID: 29775844
[No Abstract] [Full Text] [Related]
11. Chronic myelomonocytic leukemia: myeloproliferative variant.
Onida F; Beran M
Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
[TBL] [Abstract][Full Text] [Related]
12. Recent Updates on Chronic Myelomonocytic Leukemia.
Loghavi S; Khoury JD
Curr Hematol Malig Rep; 2018 Dec; 13(6):446-454. PubMed ID: 30311069
[TBL] [Abstract][Full Text] [Related]
13. How I investigate chronic myelomonocytic leukemia.
Sangiorgio VFI; Arber DA; Orazi A
Int J Lab Hematol; 2020 Apr; 42(2):101-108. PubMed ID: 31841277
[TBL] [Abstract][Full Text] [Related]
14. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
Harada Y; Harada H
Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
[TBL] [Abstract][Full Text] [Related]
15. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
16. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center].
Qu SQ; Pan LJ; Qin TJ; Xu ZF; Li B; Wang HJ; Sun Q; Jia YJ; Li CW; Cai WY; Gao QY; Jiao M; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):373-379. PubMed ID: 37550186
[No Abstract] [Full Text] [Related]
17. The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory.
Bruehl FK; Osman MM; Chen D; Dalland JC
J Hematop; 2023 Jun; 16(2):65-71. PubMed ID: 38175439
[TBL] [Abstract][Full Text] [Related]
18. Oligo-monocytic CMML and other pre-CMML states: Clinical impact, prognostication and management.
Valent P
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101137. PubMed ID: 32460976
[TBL] [Abstract][Full Text] [Related]
19. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
20. Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; D'Elia GM; Alimena G
Leuk Lymphoma; 2008 Jul; 49(7):1292-6. PubMed ID: 18604717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]